Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some general NSAID and indomethacin-related safety/administration concepts align with the provided label (e.g., indomethacin is an NSAID; adverse effects include GI/CNS effects; contraindications include NSAID/aspirin-type hypersensitivity and CABG perioperative pain; GI bleeding/ulcer and CV thrombotic risks are described). However, multiple claims are unsupported or go beyond the provided label text, including indications being described as 'commonly used' for gout/crystal arthritis beyond the specific labeled indication, ER-specific formulation/dosing assertions, and several interaction/contraindication/administration statements not supported by the label text provided.
Category Scores
Accurate Statements
Indomethacin extended-release is an oral nonsteroidal anti-inflammatory drug (NSAID).
DESCRIPTION: 'Indomethacin is a non-steroidal anti-inflammatory indole derivative...'; DOSAGE/ADMINISTRATION and INDICATIONS indicate oral capsules; label content provided does not explicitly define 'ER' but does establish indomethacin is an NSAID.
Indomethacin has been found effective... Acute gouty arthritis.
INDICATIONS AND USAGE list includes 'Acute gouty arthritis.'
Common NSAID-related side effects include stomach pain, heartburn, and nausea.
ADVERSE REACTIONS (incidence >1%): 'nausea with or without vomiting'; 'dyspepsia (including indigestion, heartburn and epigastric pain)'; 'abdominal distress or pain'.
Common NSAID-related side effects include dizziness or headache.
ADVERSE REACTIONS (incidence >1%): 'headache'; 'dizziness'.
Serious risks of NSAIDs include GI bleeding and ulcers.
WARNINGS: 'Risk of Ulceration, Bleeding, and Perforation' includes 'bleeding, ulceration, and perforation... can be fatal'; and notes risk with prior ulcer disease/GI bleeding.
Serious risks of NSAIDs include kidney problems.
WARNINGS: 'Renal Effects' includes 'Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury' and 'Renal toxicity...' plus guidance on impaired renal function.
Serious risks of NSAIDs include increased cardiovascular risk in some patients, especially with higher doses or longer use.
WARNINGS: 'Patients with known CV disease or risk factors... may be at greater risk' and recommendation: 'lowest effective dose should be used for the shortest duration possible' to minimize CV thrombotic event risk.
People often need extra caution or should avoid NSAIDs if they have a history of NSAID allergy or asthma triggered by NSAIDs.
CONTRAINDICATIONS: 'should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.'
People often need extra caution or should avoid NSAIDs if they have prior stomach ulcers or GI bleeding.
WARNINGS (Gastrointestinal Effects): 'NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding' and notes >10-fold increased risk with prior peptic ulcer disease and/or GI bleeding.
ER indomethacin products should not be crushed or chewed unless the specific product instructions say it is allowed.
No explicit label text about crushing/chewing was provided in the supplied label excerpt; therefore this statement is not supported by the provided label text.
Unsupported Statements
Indomethacin ER usually refers to indomethacin extended-release.
The supplied label excerpt describes 'extended release capsules' but does not state that 'indomethacin ER' is used as a shorthand in general or 'usually refers to' extended-release indomethacin.
Indomethacin extended-release is used to reduce pain, inflammation, and fever.
The label states indomethacin has 'antipyretic and analgesic properties' and is effective for reducing fever and relieving pain, but the provided INDICATIONS AND USAGE excerpt does not link 'extended-release' specifically to this triad as an indication statement.
ER indomethacin is designed to release more slowly over time than immediate-release indomethacin.
The provided label excerpt does not include a formulation/pharmacokinetic comparison for extended-release vs immediate-release or describe slower release behavior.
Indomethacin (including ER formulations) is commonly used for gout attacks (acute gout).
While acute gouty arthritis is an indicated use, the label excerpt does not state 'commonly used' and does not characterize usage frequency or practice patterns.
Indomethacin (including ER formulations) is commonly used for other crystal-related arthritis flares.
Only 'Acute gouty arthritis' is listed in INDICATIONS AND USAGE. No other crystal-related arthritis indications are provided.
Indomethacin (including ER formulations) is commonly used for inflammatory joint conditions where an NSAID is indicated.
The label provides specific indications (rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder bursitis/tendinitis, acute gouty arthritis). It does not provide a generalized statement about 'inflammatory joint conditions where an NSAID is indicated.'
ER indomethacin is formulated to allow less frequent dosing than immediate-release products.
The supplied label excerpt does not provide dosing frequency comparisons between ER and immediate-release.
ER indomethacin is formulated to provide steadier drug levels over a longer period.
The supplied label excerpt provides pharmacokinetic information for indomethacin capsules/suspension and half-life, but does not describe ER-specific steady levels over longer period.
ER indomethacin may be harder on the stomach like other NSAIDs.
The label supports GI risks for NSAIDs/indomethacin, but it does not contain an ER-specific statement about being 'harder on the stomach' compared with other formulations.
ER indomethacin is typically taken with routine oral medication instructions such as taking it as prescribed.
The label advises 'Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals' and dose adjustment after response, but does not contain a statement about 'typically taken with routine oral medication instructions such as taking it as prescribed.'
ER indomethacin may be taken with food if the prescriber recommends it to reduce stomach irritation.
The provided label excerpt includes a statement that a 50 mg suspension was bioequivalent to a capsule when administered with food, but it does not state that food reduces stomach irritation or that taking with food is recommended for GI irritation.
People often need extra caution or should avoid NSAIDs if they have significant kidney disease.
The label says indomethacin is 'not recommended in ... advanced renal disease' and suggests close monitoring if must be initiated. It does not support a generalized 'significant kidney disease' phrasing.
People often need extra caution or should avoid NSAIDs if they have certain heart disease or higher cardiovascular risk.
The label states patients with known CV disease or risk factors 'may be at greater risk' and recommends lowest effective dose/shortest duration, but it does not state 'should avoid' or provide a specific 'certain heart disease' avoidance instruction.
People often need extra caution or should avoid NSAIDs if they use blood thinners or other drugs that raise bleeding risk.
The label discusses caution with oral anticoagulants and higher risk of serious GI bleeding with combined use of warfarin and NSAIDs, but it does not support a generalized 'blood thinners or other drugs that raise bleeding risk' avoidance statement.
Many indomethacin products are available as generics, including extended-release versions, depending on the country and locally stocked brands.
The provided label excerpt does not discuss market availability or generic availability.
Contradictions
Low
AI Statement
Indomethacin (including ER formulations) is used to reduce pain, inflammation, and fever.
Label Reference
No direct contradiction identified in supplied label excerpt; however, the claim is partially unsupported because it is not explicitly presented as an ER-specific indication statement.
Low
AI Statement
People often need extra caution or should avoid NSAIDs if they use blood thinners or other drugs that raise bleeding risk.
Label Reference
Label supports caution with anticoagulants and synergistic GI bleeding risk with warfarin, but does not support 'avoid' language; not a direct contradiction.
Important Omissions
Specific administration instructions for the provided '75 mg extended-release capsule' formulation (e.g., exact dosing regimen, whether/how to take, titration schedule) beyond general 'adjust dose and frequency' guidance.
Importance:
Moderate
Contraindication for perioperative pain in the setting of CABG surgery (explicitly contraindicated).
Importance:
Moderate
Drug interaction specifics such as aspirin concomitant use not recommended, and listed interactions (ACE inhibitors/ARBs, digoxin, methotrexate, diflunisal, lithium, etc.).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims are generalized (e.g., ER-specific release/steady levels; dosing frequency; 'avoid' phrasing for kidney/heart disease; broad anticoagulant caution) and some administration guidance is not supported by the provided label excerpt (food to reduce irritation; take as prescribed). While the label does support major GI/CV/renal risks and key contraindications, unsupported ER-specific and practice-frequency statements could mislead label-accurate counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple ER-specific pharmacology/administration and 'commonly used'/general caution statements are not supported by the provided prescribing information excerpt; several potentially important contraindications and interaction details are omitted.
Suggested Improvement
Restrict claims to the specific labeled indications (including acute gouty arthritis and other listed diseases), avoid unsupported ER-release/steady-level and dosing-frequency comparisons, remove or qualify generalized 'avoid' language that the label does not state, and include label-specific contraindications (e.g., CABG perioperative pain) and interaction/caution statements from the provided sections.